
Pfizer Breaks Ground on New R&D Facility
The company has broken ground on a R&D and process development facility in Missouri.
On June 27, 2017, Pfizer
The facility will provide approximately 295,000 ft2 of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. This team is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms applying analytical technologies, conducting non-GMP manufacturing, and scale-up studies. According to Pfizer, this work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation and immunology, and vaccines, including biosimilars.
The campus will include a floorplan that provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces, and increased conferencing technologies where researchers can collaborate. As part of the strategic incentives package from St. Louis County and the State of Missouri, Pfizer is donating $20,000 to the local Parkway School District to support STEM education.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.